CoChat

Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study

Gerra, G., Zaimovic, A., Giusti, F., Moi, G., Brewer, C. · 2002 · Addiction Biology

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Abstract

Flumazenil (FLU), a benzodiazepine (BZD) partial agonist with a weak intrinsic activity, was previously found unable to precipitate withdrawal in tolerant subjects submitted to long‐lasting BZD treatment. The potential use of FLU to treat BZD withdrawal symptoms has also been evaluated tentatively in clinical studies. In the present experiment, FLU (treatment A) was compared with oxazepam tapering (treatment B) and placebo (treatment C) in the control of BZD withdrawal symptoms in three groups of BZD dependent patients. Group A patients (20) received FLU 1 mg twice a day for 8 days, and oxazepam 30 mg in two divided doses (15 mg + 15 mg) during the first night, oxazepam 15 mg during the second night and oxazepam 7.5 mg during the third night. FLU was injected i.v. in saline for 4 hours in the morning and 4 hours in the afternoon, in association with placebo tablets. Group B patients (20) were treated by tapering of oxazepam dosage (from 120 mg) and with saline solution (as placebo) instead of FLU for 8 days. Group C patients (10) received saline instead of FLU and placebo tablets instead of oxazepam for 8 days. FLU immediately reversed BZD effects on balance task and significantly reduced withdrawal symptoms in comparison with oxazepam and placebo on both self‐reported and observer‐rated withdrawal scales. The partial agonist also reduced craving scores during the detoxification procedure. In addition, during oxazepam tapering, group B patients experienced paradoxical symptoms that were not apparent in FLU patients. Patients treated with FLU showed a significantly lower relapse rates on days 15, 23 and 30 after the detoxification week. Our data provide further evidence of FLUs ability to counteract BZD effects, control BZD withdrawal and normalize BZD receptor function. The effectiveness of FLU may reflect its capacity to upregulate BZD receptors and to reverse the uncoupling between the recognition sites of BZD and GABA, on the GABA A macromolecular complex, that has been reported in tolerant subjects.

Overview

Integrity signals

Registry

Crossref · 10.1080/1355621021000005973

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 8

  1. Vescovi PP, 1987, Nicotinic acid effectiveness in the treatment of benzodiazepine withdrawal, CurrTherRes, 41, 429
  2. 10.1097/00004850-199611020-00002 · doi:10.1097/00004850-199611020-00002
  3. Spitzer RL, 1990, Structured Clinical Interview according to DSM‐III‐R
  4. Pfohl B, 1989, Structured Interview for Personality Disorders, revised version
  5. Hathaway SR, 1989, Minnesota Multifasic Personality Inventory‐2. Manual
  6. Wechsler CD., 1985, WAIS‐R manual
  7. Peturrson H, 1984, Dependence on tranquilizers
  8. 10.1111/j.1572-0241.2000.01866.x · doi:10.1111/j.1572-0241.2000.01866.x · Paper page

Cited by

See all 90

Metadata

Authors
Gerra, G., Zaimovic, A., Giusti, F., Moi, G., & Brewer, C.
Corresponding author
Gerra, G.
Venue
Addiction Biology
Publisher
Wiley
Published
2002-10
Volume
7
Issue
4
Pages
385-395
ISSN
  • 1355-6215 (ISSN-L)
  • 1369-1600
OpenAlex
W2091589270
Cited by
82
References
42
Citations by year
2025: 4 · 2024: 1 · 2022: 8 · 2021: 5 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 10
FWCI
0.75
Type
journal article
Language
en
Open access
closed
Locations
  • Addiction Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
Keywords
flumazenil, benzodiazepine withdrawal, benzodiazepine dependence, benzodiazepine tolerance, withdrawal symptoms, craving, detoxification, relapse, paradoxical effects, GABAA receptor
MeSH terms
Adult, Antidotes, Benzodiazepines, Blood Pressure, Cognition Disorders, Drug Administration Schedule, Female, Flumazenil, Heart Rate, Humans, Injections, Intravenous, Male, MMPI, Oxazepam, Personality Disorders, Substance Withdrawal Syndrome, Anti-Anxiety Agents, Wechsler Scales, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. https://app.cochat.ai/papers/10.1080/1355621021000005973
The paper
Gerra, G., Zaimovic, A., Giusti, F., Moi, G., & Brewer, C. (2002). Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology. https://doi.org/10.1080/1355621021000005973

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.